287 related articles for article (PubMed ID: 7561148)
1. A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes.
Zwirner J; Dobos G; Götze O
J Immunol Methods; 1995 Oct; 186(1):55-63. PubMed ID: 7561148
[TBL] [Abstract][Full Text] [Related]
2. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
3. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
5. Complement activation by cellulosic dialysis membranes.
Innes A; Farrell AM; Burden RP; Morgan AG; Powell RJ
J Clin Pathol; 1994 Feb; 47(2):155-8. PubMed ID: 8132830
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
7. Classical pathway of complement activation in mammalian kidneys.
Zwirner J; Felber E; Burger R; Bitter-Suermann D; Riethmüller G; Feucht HE
Immunology; 1993 Oct; 80(2):162-7. PubMed ID: 8262545
[TBL] [Abstract][Full Text] [Related]
8. Assessment of complement activation in clinical samples. Comparison of immunochemical and functional measurements of complement components with quantitation of activation fragments.
Maillet F; Frémeaux-Bacchi V; Uhring-Lambert B; Kazatchkine MD
J Immunol Methods; 1992 Dec; 156(2):171-8. PubMed ID: 1474254
[TBL] [Abstract][Full Text] [Related]
9. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
10. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
11. Human serum induced opsonization of immunoglobulin G-coated polystyrene microspheres with complement components C3 and C4 as measured by flow cytometry.
Spycher MO; Spycher-Burger M; Späth PJ; Burckhardt JJ
J Immunol Methods; 1991 Dec; 145(1-2):83-92. PubMed ID: 1765669
[TBL] [Abstract][Full Text] [Related]
12. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
13. Determination of C4b.C4-bp complex formed by the activation of classical complement pathway using an enzyme-linked immunosorbent assay.
Ito S; Fujita T; Tamura N
J Immunol Methods; 1987 Dec; 105(1):145-50. PubMed ID: 3500239
[TBL] [Abstract][Full Text] [Related]
14. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
Petersen NE; Elmgreen J; Teisner B; Svehag SE
Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.
Negoro N; Okamura M; Takeda T; Koda S; Amatsu K; Inoue T; Curd JG; Kanayama Y
Arthritis Rheum; 1989 Oct; 32(10):1233-42. PubMed ID: 2803326
[TBL] [Abstract][Full Text] [Related]
16. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
Kerr LD; Adelsberg BR; Schulman P; Spiera H
Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
[TBL] [Abstract][Full Text] [Related]
17. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
[TBL] [Abstract][Full Text] [Related]
18. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.
Troldborg A; Jensen L; Deleuran B; Stengaard-Pedersen K; Thiel S; Jensenius JC
Front Immunol; 2018; 9():581. PubMed ID: 29632534
[TBL] [Abstract][Full Text] [Related]
19. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
20. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
